Rheumatoid Arthritis: Daniels TE

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, Anonymous00126. · Department of Internal Medicine and Rheumatology, Ospedale Villamaria, Piombino, LI, Italy. · Ann Rheum Dis. · Pubmed #12006334 links to  free full text

Abstract: Classification criteria for Sjögren's syndrome (SS) were developed and validated between 1989 and 1996 by the European Study Group on Classification Criteria for SS, and broadly accepted. These have been re-examined by consensus group members, who have introduced some modifications, more clearly defined the rules for classifying patients with primary or secondary SS, and provided more precise exclusion criteria.

Daniels TE. · School of Dentistry, University of California, San Francisco 94143-0430, USA. · J Rheumatol Suppl. · Pubmed #11128701 No free full text.

Abstract: The salivary component of Sjögren's syndrome (SS) is defined as xerostomia (dry mouth). However, xerostomia is a common symptom associated with quantitative and qualitative changes in saliva, which are generally referred to as salivary hypofunction. This can be caused by various systemic diseases (including SS), anticholinergic effects of many drugs, psychological conditions, and physiological changes. Chronic salivary hypofunction is clinically significant because it can cause oral dysfunction, dental destruction, and mucosal infection. Evaluating patients complaining of xerostomia requires particular attention to their current medications and physical examination of the major salivary glands, teeth, and oral mucosa. Based on that information and the differential diagnosis of salivary hypofunction, appropriate tests can then be selected to develop a final diagnosis. Effective treatment of patients with chronic salivary hypofunction requires a combination of: (1) ongoing dental decay prevention and treatment supervised by their dentist; (2) salivary flow stimulation; (3) recognition and treatment of chronic oral candidiasis; (4) selective use of saliva substitutes; and (5) prescription drug review.

Gescuk B, Wu AJ, Whitcher JP, Daniels TE, Lund S, Fye K, Davis JC. · Clinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143-0633, USA. · Ann Rheum Dis. · Pubmed #15708886 links to  free full text

Abstract: BACKGROUND: Retroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome. OBJECTIVE: To examine the efficacy of the reverse transcriptase inhibitor lamivudine in patients with this syndrome. METHODS: 16 patients with primary Sjögren's syndrome were randomised to receive either lamivudine 150 mg twice daily or placebo for three months. Measures of lacrimal and salivary function, including minor salivary gland biopsies, were obtained before and after treatment. RESULTS: Treatment with lamivudine did not result in significant improvement in the primary outcome measure of unstimulated whole salivary flow or other secondary measures, including minor salivary gland biopsy focus scores. CONCLUSION: Lamivudine is not effective in patients with primary Sjögren's syndrome, suggesting either that a retroviral aetiology is not present or that it may be important only in early disease.

Daniels TE, Criswell LA, Shiboski C, Shiboski S, Lanfranchi H, Dong Y, Schiødt M, Umehara H, Sugai S, Challacombe S, Greenspan JS, Anonymous00062. · Oral Pathology, University of California at San Francisco, Box 0422, San Francisco, California 94143, USA. · Arthritis Rheum. · Pubmed #19405009 No free full text.

This publication has no abstract.